A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
Interventions: DRUG: TQ-B3525|DRUG: Fulvestrant injection
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.